Skip to content
sellModerate cluster of 4

Tyagarajan Seshu sold $93k of CADL

Chief Technology Officer at Candel Therapeutics, Inc.. 20,392 shares at an average of $4.56, traded Nov 29, 2024, filed Dec 3, 2024.

Warning score
45
Value
$93k
20,392 shares
Holdings after
125,657
-14% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

The components behind this score (role, size, price context, cluster, track record, modifiers) are shown to Pro users. Start with Pro

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0000950170-24-132932, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 29, 2024SOpen-market sale
Common Stock
-20,392$4.56$93k125,657Dec 3, 2024

Related signals

Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
50ModeratebuyCADL
Candel Therapeutics, Inc.
Manning Paul B
director
$7.5M1,250,000
45Moderatesell 4CADL
Candel Therapeutics, Inc.
Barone Francesca
Chief Scientific Officer
$101k22,081
43Moderatesell 4CADL
Candel Therapeutics, Inc.
Nichols William Garrett
Chief Medical Officer
$63k13,935
57Moderatesell 4CADL
Candel Therapeutics, Inc.
Tak Paul Peter
Chief Executive Officer
$223k48,847
25WeaksellCADL
Candel Therapeutics, Inc.
Aguilar-Cordova Estuardo
owner
$244k40,412

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.